Moreover, a prophylactic effect on bleeding frequency is reported in patients who

achieved partial success, which is paramount in preventing the development of haemophilic arthropathy at an older age [19]. Our study is of clinical importance because it shows that most of the patients with pre-ITI inhibitor titres below 40 BU mL−1 can successfully be treated with low dose ITI. As a result of its lower clotting factor use and lower frequency of infusions, this ITI regimen has several advantages. We estimate the cost to be considerably lower, compared with high dose ITI regimens [4]. Furthermore, the burden for patients and parents is lower, because of the lower frequency of FVIII infusions. Implantation of a PAC system can often be avoided, thus saving clotting factor consumption. In addition, complications such as PAC infections, which are associated with a longer time to achieve complete success, may be avoided. LY294002 cell line Disadvantages of the low dose ITI regimen may be the longer time needed to achieve success [7], and the

delay of effective prophylaxis with FVIII. this website For some patients, this may be a reason to switch to a high dose regimen. Although studies on prophylaxis with bypassing agents in inhibitor patients have reported beneficial effects, it is not an established therapy yet, and prophylaxis with bypassing agents may be less effective than with FVIII [20]. Low dose immune tolerance induction therapy is successful in severe haemophilia A patients with a pre-ITI titre below 40 BU mL−1. A shorter time to success PLEKHB2 is predicted by a maximum ITI titre below 40 BU mL−1.

In patients with a titre below 5 BU mL−1, this effect is even more pronounced (P = 0.033). We suggest that patients with severe haemophilia A and a pre-ITI inhibitor titre below 5 BU mL−1 should be treated with low dose immune tolerance induction therapy. Patients with a pre-ITI titre below 40 BU mL−1 may strongly benefit from low dose ITI regimen. However, patients with a pre-ITI inhibitor titre above 40 BU mL−1, with an anamnestic response during ITI exceeding 40 BU mL−1, or without response to the low dose regimen, should rather be treated with a high dose immune tolerance induction therapy. The authors would like to thank D.E. Fransen van de Putte for critical evaluation of the manuscript. The authors stated that they had no interests which might be perceived as posing a conflict or bias. “
“This chapter contains sections titled: Introduction Cryoprecipitate Principles of manufacture Product purity Methods of viral inactivation and elimination Potency and labeling issues Selection of products Plasma-derived concentrates for rare bleeding disorders References “
“Health-related quality of life (HRQoL) assessment is recognized as an important outcome in the evaluation of different therapeutic regimens for persons with haemophilia.